A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.
The state of Colorado submitted a revised application to the U.S. Food and Drug Administration to operation a Canadian drug importation plan in March. This blog post examines how the state’s application has changed over the years.
A March 12, 2025 memo said the state had paid more than $150,000 defending itself in a lawsuit Amgen had filed over plans to set an upper payment limit on its rheumatoid arthritis treatment, Enbrel.
Senator Jim Banks asked pointed questions about how FDA will stem the tide of semaglutide and tirzepatide coming from unknown facilities.
“Alternative funding programs” are shifting expensive prescription coverage to illegal drug importation schemes.
On March 14, the Partnership for Safe Medicines submitted comment on Customs and Border Protection’s proposed update to regulations around low-value, “de minimus” shipments.
A Texas man billed government programs millions for creams compounded by untrained teenagers. News about counterfeit medicine in six U.S. states.
FDA’s shutdown of GLP-1 compounding could lead to a new era of risk for U.S. patients.
The FDA published an update to a previous alert about undeclared active pharmaceutical ingredients in a dietary supplement to expand the package styles affected by this warning.
An FDA alert shared information on a nationwide recall of a nasal wash system due to microbrial contamination.